Libella Gene Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Employees
- -
- Market Cap
- -
Evaluation of Safety and Tolerability of Libella Gene Therapy for Alzheimer's Disease: AAV- hTERT
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2019-10-28
- Lead Sponsor
- Libella Gene Therapeutics
- Target Recruit Count
- 5
- Registration Number
- NCT04133454
- Locations
- 🇨🇴
IPS Arcasalud SAS, Zipaquirá, Cundinamarca, Colombia
Evaluation of Safety and Tolerability of Libella Gene Therapy for the Treatment of Aging: AAV- hTERT
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- Libella Gene Therapeutics
- Target Recruit Count
- 5
- Registration Number
- NCT04133649
- Locations
- 🇨🇴
IPS Arcasalud SAS, Zipaquirá, Cundinamarca, Colombia
Evaluation of Safety and Tolerability of Libella Gene Therapy for Critical Limb Ischemia: AAV- hTERT
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2019-10-28
- Lead Sponsor
- Libella Gene Therapeutics
- Target Recruit Count
- 5
- Registration Number
- NCT04110964
- Locations
- 🇨🇴
IPS Arcasalud SAS, Zipaquirá, Cundinamarca, Colombia
© Copyright 2025. All Rights Reserved by MedPath